Biomarkers play a vital role in precision medicine, from the development of novel targeted therapies and diagnostics to clinical biomarker applications. Biognosys’ Tissue Biomarker Discovery service can quantify up to 13,000 proteins per sample to identify the most promising, actionable biomarkers to support clinical decision-making.
Our Tissue Biomarker Discovery application utilizes Hyper Reaction Monitoring (HRM™) to overcome the limitations of targeted methods to identify novel biomarkers. This proprietary Biognosys technology enables specific and unbiased discovery through the quantification of complete proteomes and phospho-proteomes.
The service offers a choice of depth for the identification of differentially regulated proteins in a hypothesis-free manner. We also provide highly multiplexed targeted proteomics with absolute quantification for customized panels of proteins.
Tissue Biomarker Discovery can be applied on a large scale, analyzing thousands of proteins across thousands of samples in a high-throughput mode.
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel formats.
a) Normalized relative protein intensities for all detected proteins or absolute quantities if stable isotope standards were used
b) Protein annotation (based on Uniprot Knowledgebase)
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g. PCA)
d) Hierarchical clustering analysis
e) Functional analysis (e.g. GO/Pathway analysis)
f) Custom analysis upon request
Tissue Biomarker Discovery can be applied to all types of solid biological matrices, such as frozen tissue, FFPE slides, or cell cultures from virtually any species. Only a limited amount of material is required.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
The brochure provides you with an overview of the key features and benefits of our next-generation Biomarker Discovery solutions. In addition, the brochure elaborates on our deep a [...]
Despite significant advancements in melanoma treatment using immune checkpoint inhibitors, many patients do not show a clinical benefit. To better understand the mechanisms driving [...]